JP2014510747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510747A5 JP2014510747A5 JP2014501751A JP2014501751A JP2014510747A5 JP 2014510747 A5 JP2014510747 A5 JP 2014510747A5 JP 2014501751 A JP2014501751 A JP 2014501751A JP 2014501751 A JP2014501751 A JP 2014501751A JP 2014510747 A5 JP2014510747 A5 JP 2014510747A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- fluoro
- pharmaceutically acceptable
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 38
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000001153 fluoro group Chemical group F* 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 10
- 150000001602 bicycloalkyls Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims 4
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 claims 4
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 4
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 claims 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 4
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 125000001246 bromo group Chemical group Br* 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 2
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 claims 2
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims 2
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 claims 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 2
- ZGSNZVRXASCXRP-UHFFFAOYSA-N 5-methoxy-1h-pyrazole Chemical compound COC=1C=CNN=1 ZGSNZVRXASCXRP-UHFFFAOYSA-N 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
- USQJUMKNJWUXHW-UHFFFAOYSA-N [1]benzofuro[3,2-c]pyridine Chemical compound C1=NC=C2C3=CC=CC=C3OC2=C1 USQJUMKNJWUXHW-UHFFFAOYSA-N 0.000 claims 2
- 125000001118 alkylidene group Chemical group 0.000 claims 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 2
- UMIVXZPTRXBADB-UHFFFAOYSA-N benzocyclobutene Chemical compound C1=CC=C2CCC2=C1 UMIVXZPTRXBADB-UHFFFAOYSA-N 0.000 claims 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- -1 2- {2- [2- (bicyclo [1.1.1] pent-1-yl) -4-chlorophenoxy ] Ethyl} -7- (4-methyl-1H-imidazol-1-yl) -3,4-dihydro-2H-pyrido [1,2-a] pyrazine-1,6-dione Compound Chemical class 0.000 claims 1
- IVDMVAFKQDDZGH-AWEZNQCLSA-N 2-[(2s)-1-[4-chloro-2-(trifluoromethyl)phenoxy]propan-2-yl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound C([C@H](C)N1C(C=2N(C(C(N3C=C(C)N=C3)=CC=2)=O)CC1)=O)OC1=CC=C(Cl)C=C1C(F)(F)F IVDMVAFKQDDZGH-AWEZNQCLSA-N 0.000 claims 1
- CZEVSRPJHTVIAG-AWEZNQCLSA-N 2-[(2s)-1-[4-fluoro-2-(trifluoromethyl)phenoxy]propan-2-yl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound C([C@H](C)N1C(C=2N(C(C(N3C=C(C)N=C3)=CC=2)=O)CC1)=O)OC1=CC=C(F)C=C1C(F)(F)F CZEVSRPJHTVIAG-AWEZNQCLSA-N 0.000 claims 1
- WNKIZPPVGKAWKE-UHFFFAOYSA-N 2-[2-[(2,2-difluoro-1,3-benzodioxol-4-yl)oxy]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound C1=NC(C)=CN1C(C1=O)=CC=C2N1CCN(CCOC=1C=3OC(F)(F)OC=3C=CC=1)C2=O WNKIZPPVGKAWKE-UHFFFAOYSA-N 0.000 claims 1
- LEHPUPBPVUBARN-UHFFFAOYSA-N 2-[2-[(2,2-difluoro-1,3-dihydroinden-4-yl)oxy]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound C1=NC(C)=CN1C(C1=O)=CC=C2N1CCN(CCOC=1C=3CC(F)(F)CC=3C=CC=1)C2=O LEHPUPBPVUBARN-UHFFFAOYSA-N 0.000 claims 1
- HTPYICLKDABRCS-UHFFFAOYSA-N 2-[2-[2-(3,3-difluorocyclobutyl)-4-fluorophenoxy]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound C1=NC(C)=CN1C(C1=O)=CC=C2N1CCN(CCOC=1C(=CC(F)=CC=1)C1CC(F)(F)C1)C2=O HTPYICLKDABRCS-UHFFFAOYSA-N 0.000 claims 1
- WOARPCISPWAXFG-UHFFFAOYSA-N 2-[2-[2-(3-bicyclo[1.1.1]pentanyl)phenoxy]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound C1=NC(C)=CN1C(C1=O)=CC=C2N1CCN(CCOC=1C(=CC=CC=1)C13CC(C1)C3)C2=O WOARPCISPWAXFG-UHFFFAOYSA-N 0.000 claims 1
- XNTCGZXHDJPICB-UHFFFAOYSA-N 2-[2-[4-fluoro-2-(1,1,1-trifluoro-2-methylpropan-2-yl)phenoxy]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound C1=NC(C)=CN1C(C1=O)=CC=C2N1CCN(CCOC=1C(=CC(F)=CC=1)C(C)(C)C(F)(F)F)C2=O XNTCGZXHDJPICB-UHFFFAOYSA-N 0.000 claims 1
- YQSXKNVPEQLXJQ-UHFFFAOYSA-N 2-[2-[[4-fluoro-2-(trifluoromethyl)-1,3-benzothiazol-7-yl]oxy]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound C1=NC(C)=CN1C(C1=O)=CC=C2N1CCN(CCOC=1C=3SC(=NC=3C(F)=CC=1)C(F)(F)F)C2=O YQSXKNVPEQLXJQ-UHFFFAOYSA-N 0.000 claims 1
- AHERSACVYXVWEK-UHFFFAOYSA-N 7-(4-methylimidazol-1-yl)-2-[2-[2-[2-(trifluoromethyl)-1,3-thiazol-4-yl]phenoxy]ethyl]-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound C1=NC(C)=CN1C(C1=O)=CC=C2N1CCN(CCOC=1C(=CC=CC=1)C=1N=C(SC=1)C(F)(F)F)C2=O AHERSACVYXVWEK-UHFFFAOYSA-N 0.000 claims 1
- XNBWJMQONCSXNL-UHFFFAOYSA-N 7-(4-methylimidazol-1-yl)-2-[2-[2-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]phenoxy]ethyl]-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound C1=NC(C)=CN1C(C1=O)=CC=C2N1CCN(CCOC=1C(=CC=CC=1)C=1SN=C(N=1)C(F)(F)F)C2=O XNBWJMQONCSXNL-UHFFFAOYSA-N 0.000 claims 1
- WANTWYYPVUJSRC-UHFFFAOYSA-N 7-(4-methylimidazol-1-yl)-2-[2-[2-[3-(trifluoromethyl)-1,2-oxazol-5-yl]phenoxy]ethyl]-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound C1=NC(C)=CN1C(C1=O)=CC=C2N1CCN(CCOC=1C(=CC=CC=1)C=1ON=C(C=1)C(F)(F)F)C2=O WANTWYYPVUJSRC-UHFFFAOYSA-N 0.000 claims 1
- VVMAQBKWLDOZMB-UHFFFAOYSA-N 7-(4-methylimidazol-1-yl)-2-[2-[[2-(trifluoromethyl)-1,3-benzothiazol-7-yl]oxy]ethyl]-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound C1=NC(C)=CN1C(C1=O)=CC=C2N1CCN(CCOC=1C=3SC(=NC=3C=CC=1)C(F)(F)F)C2=O VVMAQBKWLDOZMB-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 1
- 229940127236 atypical antipsychotics Drugs 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 claims 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470076P | 2011-03-31 | 2011-03-31 | |
| US61/470,076 | 2011-03-31 | ||
| US201261599022P | 2012-02-15 | 2012-02-15 | |
| US61/599,022 | 2012-02-15 | ||
| PCT/IB2012/051348 WO2012131539A1 (en) | 2011-03-31 | 2012-03-21 | Novel bicyclic pyridinones |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510747A JP2014510747A (ja) | 2014-05-01 |
| JP2014510747A5 true JP2014510747A5 (https=) | 2014-06-19 |
| JP5767393B2 JP5767393B2 (ja) | 2015-08-19 |
Family
ID=45937491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501751A Expired - Fee Related JP5767393B2 (ja) | 2011-03-31 | 2012-03-21 | 新規二環式ピリジノン |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8697673B2 (https=) |
| EP (1) | EP2691393B1 (https=) |
| JP (1) | JP5767393B2 (https=) |
| AR (1) | AR085748A1 (https=) |
| CA (1) | CA2830027C (https=) |
| ES (1) | ES2602794T3 (https=) |
| TW (1) | TW201300384A (https=) |
| UY (1) | UY33978A (https=) |
| WO (1) | WO2012131539A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA019685B1 (ru) | 2009-02-06 | 2014-05-30 | Янссен Фармасьютикалз, Инк. | Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| BRPI1011190A8 (pt) | 2009-05-07 | 2016-11-16 | Janssen Pharmaceuticals Inc | Derivados de indazol e aza-indazol substituídos como moduladores de gama secretase |
| ES2519565T3 (es) | 2009-07-15 | 2014-11-07 | Janssen Pharmaceuticals Inc. | Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa |
| EP2523949B1 (en) | 2010-01-15 | 2014-08-20 | Janssen Pharmaceuticals Inc. | Novel substituted triazole derivatives as gamma secretase modulators |
| CA2827969A1 (en) | 2011-03-24 | 2012-09-27 | Janssen Pharmaceuticals, Inc. | Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
| TWI567079B (zh) | 2011-07-15 | 2017-01-21 | 健生醫藥公司 | 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物 |
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| NZ702611A (en) | 2012-05-16 | 2016-10-28 | Cellzome Ltd | Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| BR112015007782A2 (pt) * | 2012-10-12 | 2017-07-04 | Teva Pharma | laquinimod para reduzir danos talâmicos na esclerose múltipla |
| JP2014101316A (ja) * | 2012-11-20 | 2014-06-05 | Toyobo Co Ltd | ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法 |
| AU2013366668B2 (en) * | 2012-12-20 | 2017-07-20 | Janssen Pharmaceutica Nv | Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators |
| ES2612215T3 (es) | 2013-01-17 | 2017-05-12 | Janssen Pharmaceutica, N.V. | Novedosos derivados de pirido-piperazinona sustituidos como moduladores de gamma secretasa |
| JP6425717B2 (ja) * | 2013-10-04 | 2018-11-21 | ファイザー・インク | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| CA2934891C (en) * | 2014-01-16 | 2023-02-28 | Nicholas Ryan DEPREZ | Pyrimidinyloxy benzene derivatives as herbicides |
| CN103787839B (zh) * | 2014-01-21 | 2015-12-02 | 苏州昊帆生物科技有限公司 | 合成2,3,4,5,6-五氟苯酚的方法 |
| AP2016009465A0 (en) | 2014-04-01 | 2016-09-30 | Pfizer | Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators |
| CN103965093A (zh) * | 2014-04-04 | 2014-08-06 | 华南理工大学 | 2-全氟烷基吲哚类化合物及其制备方法和应用 |
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| MX368391B (es) | 2015-02-03 | 2019-09-30 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas. |
| WO2016201168A1 (en) | 2015-06-10 | 2016-12-15 | Forum Pharmceuticals Inc. | Oxadiazine compounds and methods of use thereof |
| WO2017210371A2 (en) * | 2016-05-31 | 2017-12-07 | Human Biomolecular Research Institute | Compounds as inhibitors of sodium channels |
| WO2018031680A1 (en) * | 2016-08-10 | 2018-02-15 | Fronthera U.S. Pharmaceuticals Llc | Novel compounds, uses and methods for their preparation |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN110256369A (zh) * | 2019-07-01 | 2019-09-20 | 中国人民大学 | 一种制备多氟烷基取代的异恶唑化合物的方法 |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1419788A (en) | 1972-08-02 | 1975-12-31 | Pfizer | Herbicidal method using 2-trifuluromethyl-4-quinolinols |
| EP0585913B1 (en) | 1992-09-04 | 1997-12-29 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
| ATE239797T1 (de) | 1993-01-25 | 2003-05-15 | Takeda Chemical Industries Ltd | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
| EP0733632B1 (en) | 1995-03-24 | 2003-06-04 | Takeda Chemical Industries, Ltd. | Cyclic compounds, their production and use as tachykinin receptor antagonists |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| NZ337765A (en) | 1997-04-09 | 2001-09-28 | Mindset Biopharmaceuticals Usa | Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| KR100398178B1 (ko) | 1998-03-03 | 2003-10-10 | 피피지 인더스트리즈 오하이오 인코포레이티드 | 침윤된 유리 섬유 스트랜드 및 이를 포함한 제품 |
| US20020132817A1 (en) | 1998-03-19 | 2002-09-19 | Hideaki Natsugari | Heterocyclic compounds, their production and use |
| CA2352612A1 (en) | 1998-11-27 | 2000-06-08 | Hideo Fukui | Pharmaceuticals |
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| CA2427661C (en) | 2000-11-03 | 2013-05-28 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| CA2498111A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| US20040146512A1 (en) | 2002-10-09 | 2004-07-29 | Arnon Rosenthal | Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| WO2004035577A2 (en) | 2002-10-16 | 2004-04-29 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| BRPI0410630A (pt) | 2003-06-19 | 2006-06-13 | Pfizer Prod Inc | antagonista de nk1 |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| CA2554387A1 (en) | 2004-01-28 | 2005-08-11 | Merck & Co., Inc. | Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity |
| EP1720847A1 (en) | 2004-02-02 | 2006-11-15 | Pfizer Products Incorporated | Histamine-3 receptor modulators |
| US7820680B2 (en) | 2004-03-09 | 2010-10-26 | Merck & Co., Inc. | HIV integrase inhibitors |
| WO2005117904A2 (en) | 2004-04-14 | 2005-12-15 | Gilead Sciences, Inc. | Phosphonate analogs of hiv integrase inhibitor compounds |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| FR2877015B1 (fr) | 2004-10-21 | 2007-10-26 | Commissariat Energie Atomique | Revetement nanostructure et procede de revetement. |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| US20090074775A1 (en) | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| WO2006121831A2 (en) | 2005-05-10 | 2006-11-16 | Merck & Co., Inc. | Hiv integrase inhibitors |
| CA2608018C (en) | 2005-05-12 | 2010-07-13 | Pfizer Inc. | Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
| CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
| DE602006018301D1 (de) | 2005-06-22 | 2010-12-30 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
| TW200713011A (en) | 2005-09-30 | 2007-04-01 | Hon Hai Prec Ind Co Ltd | System, method and electrical apparatus for data transferring |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| EP1948614A2 (en) | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
| KR20080069221A (ko) | 2005-11-24 | 2008-07-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모르폴린 타입의 신나미드 화합물 |
| US20070117839A1 (en) | 2005-11-24 | 2007-05-24 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| CN102702044A (zh) * | 2006-01-20 | 2012-10-03 | 先灵公司 | 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物 |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| CA2643055A1 (en) | 2006-03-13 | 2007-09-20 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| AU2007242555B2 (en) | 2006-04-21 | 2010-12-16 | Pfizer Products Inc. | Pyridine[3,4-b]pyrazinones |
| AU2007254190A1 (en) | 2006-05-16 | 2007-11-29 | Gilead Sciences, Inc. | Integrase inhibitors |
| JPWO2007135969A1 (ja) | 2006-05-19 | 2009-10-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア系−シンナミド誘導体 |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| JP4585610B2 (ja) | 2007-01-22 | 2010-11-24 | ファイザー・プロダクツ・インク | 治療用化合物のトシル酸塩およびその医薬組成物 |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| US8252803B2 (en) | 2007-02-12 | 2012-08-28 | Merck Sharp & Dohme Corp. | Piperidine derivatives |
| CL2008000582A1 (es) | 2007-02-28 | 2008-06-27 | Eisai R&D Man Co Ltd | Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis. |
| WO2008137102A2 (en) | 2007-05-04 | 2008-11-13 | Torreypines Therapeutics, Inc. | Methods of modulating amyloid beta and compounds useful therefor |
| RU2009144998A (ru) | 2007-05-07 | 2011-06-20 | Шеринг Корпорейшн (US) | Модуляторы гамма-секретазы |
| KR101138045B1 (ko) | 2007-05-11 | 2012-04-24 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타에 대한 조절제로서의 헤트아릴아닐린 |
| CA2689930A1 (en) | 2007-06-01 | 2008-12-18 | Schering Corporation | Gamma secretase modulators |
| CA2689948A1 (en) | 2007-06-01 | 2008-12-18 | Schering Corporation | Gamma secretase modulators |
| EP2166854A4 (en) | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS |
| CL2008001914A1 (es) | 2007-06-29 | 2009-07-17 | Schering Corp | Compuestos heterociclicos de nitrogeno y oxigeno,moduladores de gama secretasa, composicion farmaceutica de dichos compuestos; kit farmaceutico y su uso para prevenir o tratar enfermedades asociadas al sistema nervioso central como alzheimer, sindrome de down, enfermedades neurodegenerativas, inhibir el deposito de proteina amiloide. |
| CA2695543A1 (en) | 2007-08-06 | 2009-02-12 | Schering Corporation | Gamma secretase modulators |
| US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
| BRPI0815773A2 (pt) | 2007-08-31 | 2019-09-24 | Eisai R&D Man Co Ltd | composto, e, medicamento. |
| US8518975B2 (en) | 2007-09-06 | 2013-08-27 | Merck Sharp + Dohme Corp. | Gamma secretase modulators |
| AR068636A1 (es) | 2007-09-28 | 2009-11-25 | Schering Corp | Moduladores de la gamma secretasa |
| GB0720444D0 (en) | 2007-10-18 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
| MX2010005028A (es) | 2007-11-05 | 2010-05-27 | Schering Corp | Moduladores de gamma secretasa. |
| MX2010006244A (es) * | 2007-12-06 | 2010-12-02 | Schering Corp | Moduladores de gamma secretasa. |
| WO2009076337A1 (en) | 2007-12-11 | 2009-06-18 | Schering Corporation | Gamma secretase modulators |
| EP2227471A1 (en) | 2007-12-11 | 2010-09-15 | Schering Corporation | Gamma secretase modulators |
| AU2008335709A1 (en) | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
| WO2009087127A1 (en) | 2008-01-11 | 2009-07-16 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| JP5328816B2 (ja) | 2008-02-22 | 2013-10-30 | エフ．ホフマン−ラ ロシュ アーゲー | アミロイドβの調節薬 |
| JP2011513323A (ja) | 2008-02-29 | 2011-04-28 | シェーリング コーポレイション | アルツハイマー病の治療のためのγ−セクレターゼモジュレーター |
| US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| JP2011520809A (ja) | 2008-05-05 | 2011-07-21 | アムジエン・インコーポレーテツド | γセクレターゼモジュレーターとしての尿素化合物 |
| TW201006801A (en) | 2008-07-18 | 2010-02-16 | Lilly Co Eli | Imidazole carboxamides |
| EP2312945A4 (en) | 2008-08-13 | 2012-05-09 | Merck Sharp & Dohme | PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER |
| WO2010019393A1 (en) | 2008-08-13 | 2010-02-18 | Merck Sharp & Dohme Corp. | Pyrimidine derivatives for treatment of alzheimer's disease |
| BRPI0917144A2 (pt) | 2008-08-27 | 2015-08-04 | Eisai R&D Man Co Ltd | Processo para preparar compostos, processo para preparar uma mistura, sais de d-dbta, de d-dpta e de ácido (+) -n- (1-feniletila) ftalâmico ((+) -pepa), e, composto. |
| WO2010040661A1 (en) | 2008-10-09 | 2010-04-15 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| AU2009313527A1 (en) | 2008-11-06 | 2010-05-14 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| MX2011004680A (es) | 2008-11-06 | 2011-05-25 | Astrazeneca Ab | Moduladores de beta amiloide. |
| AU2009313524A1 (en) | 2008-11-06 | 2010-05-14 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| AU2009312856A1 (en) | 2008-11-10 | 2010-05-14 | F. Hoffmann-La Roche Ag | Heterocyclic gamma secretase modulators |
| WO2010071741A1 (en) | 2008-12-16 | 2010-06-24 | Merck Sharp & Dohme Corp. | Triazole derivatives for treatment of alzheimer's disease |
| EP2379075A4 (en) | 2008-12-16 | 2012-05-30 | Merck Sharp & Dohme | TRIAZOL DERIVATIVES FOR THE TREATMENT OF ALZHEIMER DISEASE |
| PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| EP2379563B1 (en) | 2008-12-22 | 2014-07-16 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| WO2010075204A2 (en) | 2008-12-22 | 2010-07-01 | Schering Corporation | Gamma secretase modulators |
| TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
| EA019685B1 (ru) | 2009-02-06 | 2014-05-30 | Янссен Фармасьютикалз, Инк. | Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| JP2012051807A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | アリールイミダゾール化合物 |
| JP2012051805A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | テトラヒドロトリアゾロピリジン誘導体の製造方法 |
| JP2012121809A (ja) | 2009-02-26 | 2012-06-28 | Eisai R & D Management Co Ltd | 多環式化合物の製造法およびその中間体 |
| JP2012051806A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | イミダゾリルピラジン誘導体 |
| EP2401277A1 (en) | 2009-02-26 | 2012-01-04 | Eisai R&D Management Co., Ltd. | Salt of tetrahydrotriazolopyridine derivative and crystal thereof |
| CA2751534A1 (en) | 2009-03-03 | 2010-09-10 | Pfizer Inc. | Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators |
| NZ702611A (en) | 2012-05-16 | 2016-10-28 | Cellzome Ltd | Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease |
| EP3119347B1 (en) | 2014-03-21 | 2023-06-07 | Align Technology, Inc. | Segmented orthodontic appliance with elastics |
-
2012
- 2012-03-21 CA CA2830027A patent/CA2830027C/en not_active Expired - Fee Related
- 2012-03-21 EP EP12713360.1A patent/EP2691393B1/en not_active Not-in-force
- 2012-03-21 ES ES12713360.1T patent/ES2602794T3/es active Active
- 2012-03-21 JP JP2014501751A patent/JP5767393B2/ja not_active Expired - Fee Related
- 2012-03-21 WO PCT/IB2012/051348 patent/WO2012131539A1/en not_active Ceased
- 2012-03-28 UY UY0001033978A patent/UY33978A/es not_active Application Discontinuation
- 2012-03-28 TW TW101110869A patent/TW201300384A/zh unknown
- 2012-03-29 US US13/433,452 patent/US8697673B2/en active Active
- 2012-03-29 AR ARP120101073A patent/AR085748A1/es not_active Application Discontinuation
-
2013
- 2013-10-15 US US14/053,924 patent/US9067934B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510747A5 (https=) | ||
| JP2024542692A5 (https=) | ||
| JP2013508413A5 (https=) | ||
| HRP20110335T1 (hr) | Supstituirani biciklolaktamski spojevi | |
| JP2013508412A5 (https=) | ||
| JP2009525275A (ja) | 多環式１，２，３，４−テトラヒドロ−イソキノリン誘導体およびｐｐａｒモジュレーターとしてのそれらを含む組成物 | |
| JP2011500550A5 (https=) | ||
| JP2016515536A5 (https=) | ||
| KR20090024820A (ko) | 인간 단백질 티로신 포스파타아제 억제제 및 이용 방법 | |
| JP2009525984A5 (https=) | ||
| JP2013521260A5 (https=) | ||
| JP2009540009A5 (https=) | ||
| JP2014532626A5 (https=) | ||
| JP2009524670A5 (https=) | ||
| JP2016506419A5 (https=) | ||
| JP2016515562A5 (https=) | ||
| AU2006300422A1 (en) | Triarylcarboxylic acid derivative | |
| CA2643272A1 (en) | Gent for treating or preventing digestive ulcer | |
| JP2007520471A5 (https=) | ||
| JP2023521351A5 (https=) | ||
| JP2010504286A5 (https=) | ||
| JP2013544877A5 (https=) | ||
| JP2013521325A5 (https=) | ||
| JP2009519903A5 (https=) | ||
| TW200946514A (en) | Activator for peroxisome proliferator-activated receptor |